Helius Medical Technologies, INC

Solana Company has amended its sales agreement to increase its at-the-market equity offering capacity to $250 million.

Solana Company stockholders elected six directors and ratified the appointment of CBIZ CPAs P.C. as the independent auditor for 2026.

Solana Company announced the completion of a registered direct offering, raising approximately $7.9 million in net proceeds to fund its digital asset treasury and general corporate purposes.

Solana Company reports the mutual agreement for Dr. Antonella Favit-Van Pelt to resign as Chief Medical Officer, effective April 8, 2026, with a separation agreement including a $875,000 payment.

Solana Company announced the appointment of Madelene Gani as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026, to drive growth and institutionalize the ecosystem.

Solana Company reported a significant net loss of $352.8 million for Q3 2025, primarily driven by non-cash charges related to its new digital asset treasury strategy.

Solana Company reports a $99.8 million net loss for Q1 2026 driven by digital asset volatility and announces a major executive leadership transition.

Solana Company transformed into a Solana token treasury vehicle, raised over $500M via PIPE/ATM, amassed $350M of SOL by 9/30, but recorded a $352.8M Q3 net loss driven by derivative warrant liabilities and financing costs.

Helius Medical Technologies reported a significantly wider net loss in Q2 2025 due to decreased product sales, despite successful capital raises and regaining Nasdaq compliance.

Helius Medical Technologies reports a net loss for Q1 2025, faces Nasdaq compliance issues, and continues to pursue strategic alternatives.

Helius Medical Technologies reported a net loss of $3.7 million for the third quarter of 2024, facing challenges with reimbursement pricing and manufacturing transitions.

Helius Medical Technologies reported a net loss of $1.6 million for the second quarter of 2024, while making progress on commercialization and reimbursement efforts for its PoNS device.

Solana Company, formerly Helius Medical Technologies, Inc., has strategically shifted its focus to a digital asset treasury centered on Solana tokens, reporting a net loss of $40.9 million for 2025 amidst significant market volatility.

Helius Medical Technologies announces its 2024 financial results, highlighting progress in commercialization and regulatory efforts while addressing ongoing reimbursement hurdles.

Helius Medical Technologies' 2023 annual report details ongoing losses, a manufacturing transition, and progress towards reimbursement for its PoNS device.

Summer Wisdom Holdings Ltd reported changes in beneficial ownership of Helius Medical Technologies, Inc. common stock on May 11, 2026.

Director Cosmo Yi Jiang exercised warrants for 1,005,040 shares of Solana Co common stock and withheld 610 shares for tax obligations.

Director Cosmo Yi Jiang acquired 1,005,040 warrants for Solana Co (HSDT) via a transfer agreement with Pantera Capital.

Solana Co Director Sergio Mello was granted restricted stock units and stock options under the company's equity incentive plan.

Director Michel Kai Tai Lee of Solana Co was granted stock options and restricted stock units under the company's equity incentive plan.

Solana Co Director Edward M. Straw was granted restricted stock units and stock options under the company's equity incentive plan.

Solana Company announces its 2026 Annual Meeting of Stockholders, set for May 21, 2026, to elect directors and ratify auditor appointment.

Solana Company calls a special meeting to approve significant share issuances for crypto-related warrants, expand its equity incentive plan, and elect a new director amidst a strategic pivot to digital assets.

Helius Medical Technologies is calling a special meeting to vote on proposals including a reverse stock split to meet Nasdaq requirements, increasing authorized shares, and approving potential financing.

Helius Medical Technologies is asking stockholders to approve a reverse stock split and the issuance of shares upon warrant exercises to comply with Nasdaq listing requirements at its upcoming annual meeting.

Helius Medical Technologies releases a supplement to its proxy statement clarifying the quorum requirements for its upcoming Annual Meeting of Stockholders on June 27, 2024.

Helius Medical Technologies is asking stockholders to approve an amendment to its 2022 Equity Incentive Plan at the upcoming annual meeting on June 27, 2024, to increase the number of shares available for issuance and ensure continued attraction and retention of key personnel.

Helius Medical Technologies, a neurotechnology company, has filed an S-1 registration statement for a public offering of common stock and warrants, seeking to raise approximately $13.6 million to address immediate financial needs and Nasdaq listing compliance, while facing substantial dilution for new investors.

Helius Medical Technologies is seeking to raise capital through a best efforts public offering of common stock, pre-funded warrants, and accompanying warrants.

Helius Medical Technologies is undertaking a best efforts public offering of common stock, warrants, and pre-funded warrants to raise capital for operations and working capital.

Pantera Capital entities have amended their Schedule 13D filing to reflect an adjustment in their beneficial ownership of Solana Company's Class A Common Stock following a warrant exercise.

Choon Wee Chee, Executive Chairman of Solana Company, has increased his beneficial ownership to 20.2% following the settlement of restricted stock units.

Fusion Summer Limited, controlled by Executive Chairman CHEE Choon Wee, acquired 17.0% of Helius Medical Technologies' Class A Common Stock for approximately $47.0 million.

Pantera Capital and its founder Daniel W. Morehead have disclosed a significant 9.67% beneficial ownership stake in Helius Medical Technologies, Inc., including common stock and pre-funded warrants.

Polar Asset Management Partners Inc. has disclosed a beneficial ownership of 4.0% in Solana Co's Class A Common Stock, holding 2,305,169 shares.

Solana Rocket Holdings Limited and CHUNG Wai Shing have filed an amended Schedule 13G reporting a 9.99% beneficial ownership stake in Solana Co.

Kathmere Capital Management, LLC has reported a passive 8.7% beneficial ownership stake in Solana Co's Class A Common Stock.

Polar Asset Management Partners Inc. has reported a 5.8% beneficial ownership stake in Solana Co, including shares from warrants.

Solana Rocket Holdings Limited and its controlling shareholder, CHUNG Wai Shing, have disclosed a 9.99% beneficial ownership stake in Solana Co, capped by a beneficial ownership blocker.

Solana Rocket Holdings Limited and its controlling shareholder, CHUNG Wai Shing, reported a 9.99% beneficial ownership stake in Helius Medical Technologies, Inc.